LONDON (Alliance News) - Horizon Discovery PLC Thursday said Chief Executive Officer Darrin Disley bought 10,000 shares at a price of 145 pence per share. Following this transaction, Disley's direct beneficial interest is 682,523 shares, representing 1.02% of the total issued share capital. Read More

Horizon Discovery Gets UK Research Grant For Cancer Diagnostics

16th Jun 2014 10:22

LONDON (Alliance News) - Horizon Discovery Group PLC Monday said it has been awarded a GBP360,224 research grant from the UK's Technology Strategy Board, together with life sciences testing firm LGC Ltd to develop standardisation for next-generation cancer diagnostics. Horizon said it will Read More

Horizon Discovery Licenses Broad Institute's Gene Editing System

12th Jun 2014 12:28

LONDON (Alliance News) - Horizon Discovery Group PLC said Thursday it has licensed the Broad Institute's CRISPR/Cas9 gene editing system, which is used to mutate or change genes in living cells. The Broad Institute is a research centre in the US state of Massachusetts, connected with the Ma Read More

DIRECTOR DEALINGS: Horizon Discovery Non-Executive Buys Shares

11th Jun 2014 11:41

LONDON (Alliance News) - Life science company Horizon Discovery Group PLC Wednesday said Non-Executive Director Susan Searle purchased 16,000 shares at 159.96 pence per share for her self-invested personal pension fund. Following this transaction, Searle holds 20,000 shares, which represent Read More

Horizon Discovery Adds US Screening Business To Portfolio

15th May 2014 14:02

LONDON (Alliance News) - Horizon Discovery Group PLC, the biotechnology company that listed on AIM earlier this year, Thursday said it had bought the CombinatoRx service business and assets from Zalicus for GBP4.7 million, a deal that will give it a revenue generating screening business supported Read More

1 2 3 4 5 678

FTSE 100 Latest

Value8,809.74

Change53.53